Galectin Therapeutics Inc
Research Galectin Therapeutics Inc (GALT) on Bullrun: market cap USD 264.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGALT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 264.58M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 5.05M
- Free cash flow-USD 3.87M
Valuation Snapshot
latest market cap is USD 264.58M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 30.84M | -USD 23.88M | n/a | -0.48 | USD 17.72M | USD 133.76M | -USD 127.92M |
| FY2024 | USD 0 | -USD 47.05M | -USD 41.77M | n/a | -0.76 | USD 15.12M | USD 106.25M | -USD 104.79M |
| FY2023 | n/a | -USD 41.07M | -USD 32.97M | n/a | -0.74 | USD 25.66M | USD 71.79M | -USD 61.96M |
| FY2022 | n/a | -USD 38.78M | n/a | n/a | -0.65 | USD 18.59M | USD 29.62M | -USD 33.92M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 264.58M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 271.24M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 81.47M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 102.67M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 67.15M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 122.84M | n/a | n/a | n/a |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Galectin Therapeutics Inc's market cap?
Galectin Therapeutics Inc's market capitalization is USD 264.58M.
What does Galectin Therapeutics Inc do?
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration.